Publications by authors named "Paul D Nathan"

Claim this Profile
A
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance Fernandez, Paul D Nathan

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
Sarah Howlett, Thomas J Carter, Heather M Shaw, Paul D Nathan

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
Hussein A Tawbi, Caroline Robert, Jan C Brase, Daniel Gusenleitner, Eduard Gasal, Paul D Nathan

J Immunother Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.
Reinhard Dummer, Georgina V Long, Caroline Robert, Hussein A Tawbi, Keith T Flaherty, Paul D Nathan

J Clin Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.
Jan C Brase, Robert F H Walter, Alexander Savchenko, Daniel Gusenleitner, James Garrett, Paul D Nathan

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, Georgina V Long, Keith T Flaherty, Paul D Nathan

Lancet Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, Mario Mandalà, Paul D Nathan

Nat Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Hannah L Buckley, Fiona J Collinson, Gemma Ainsworth, Heather Poad, Louise Flanagan, Paul D Nathan

BMC Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Paul D Nathan

N Engl J Med· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis.
Romaana Mir, Heather M Shaw, Paul D Nathan

Melanoma Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic disease from uveal melanoma: treatment options and future prospects.
Richard D Carvajal, Gary K Schwartz, Tongalp Tezel, Brian Marr, Jasmine H Francis, Paul D Nathan

Br J Ophthalmol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trametinib in metastatic melanoma.
Neha Chopra, Paul D Nathan

Expert Rev Anticancer Ther· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Victoria L Bridgeman, Elaine Wan, Shane Foo, Mark R Nathan, Jonathan C Welti, Paul D Nathan

Mol Cancer Ther· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Richard D Carvajal, Gary K Schwartz, Helen Mann, Ian Smith, Paul D Nathan

BMC Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
Judy W King, Paul D Nathan

Future Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.
Chooi Peng Lee, N Jane Taylor, Gerhardt Attard, Simon Pacey, Paul D Nathan

Oncologist· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Pippa G Corrie, Andrea Marshall, Janet A Dunn, Mark R Middleton, Paul D Nathan

Lancet Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vemurafenib in melanoma.
Heather M Shaw, Paul D Nathan

Expert Rev Anticancer Ther· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, Margaret A Marshall, Cornelis J A Punt, John B Haanen, Paul D Nathan

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
Tim Eisen, Heikki Joensuu, Paul D Nathan, Peter G Harper, Marek Z Wojtukiewicz

Lancet Oncol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
Paul D Nathan, Anup Vinayan, David Stott, Jaspal Juttla, Vicky Goh

Cancer Biol Ther· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis.
Elaine C Jolly, Menna R Clatworthy, Christopher Lawrence, Paul D Nathan, Ken Farrington

NDT Plus· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The biological treatment of renal-cell carcinoma and melanoma.
Paul D Nathan, Tim G Eisen

Lancet Oncol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis